Bank of America
CERE

Bank of America’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bank of America’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-338,455
Closed -$13.8M – 8543
2024
Q2 		$13.8M Buy
338,455
+117,548
+53% +$4.9M ﹤0.01% 2615
2024
Q1 		$9.34M Buy
220,907
+148,612
+206% +$6.24M ﹤0.01% 3046
2023
Q4 		$3.07M Sell
72,295
-69,220
-49% -$1.99M ﹤0.01% 3977
2023
Q3 		$3.09M Buy
141,515
+965
+0.7% +$24.1K ﹤0.01% 3846
2023
Q2 		$4.47M Sell
140,550
-134,826
-49% -$4.14M ﹤0.01% 3518
2023
Q1 		$6.72M Buy
275,376
+50,804
+23% +$1.49M ﹤0.01% 3233
2022
Q4 		$7.08M Buy
224,572
+112,212
+100% +$3.17M ﹤0.01% 3033
2022
Q3 		$3.17M Buy
112,360
+89,963
+402% +$2.68M ﹤0.01% 3841
2022
Q2 		$592K Sell
22,397
-44,793
-67% -$1.27M ﹤0.01% 5302
2022
Q1 		$2.35M Sell
67,190
-9,828
-13% -$287K ﹤0.01% 4433
2021
Q4 		$2.5M Buy
77,018
+41,363
+116% +$1.46M ﹤0.01% 4338
2021
Q3 		$1.05M Buy
35,655
+30,466
+587% +$855K ﹤0.01% 5020
2021
Q2 		$133K Sell
5,189
-9,817
-65% -$141K ﹤0.01% 6349
2021
Q1 		$206K Buy
15,006
+14,958
+31,163% +$219K ﹤0.01% 6019
2020
Q4 		$1K Buy
+48
New +$623 ﹤0.01% 7028

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Bank of America's CERE Position: Q3 2024 in Review

Bank of America sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 338,455 shares — an estimated $13.8M sold.

Bank of America first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $13.8M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Bank of America reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Bank of America sold 338,455 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $13.8M.
  • Bank of America first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Bank of America's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $13.8M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.